Skip to content

Study · Randomized controlled trial · n = 227 · 2002

7 results

Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate).

Schmid P, Untch M, Wallwiener D, Kossé V, Bondar G, Vassiljev L, Tarutinov V, Kienle E, Lüftner D, Possinger K

Anticancer research1 Jul 2002Cited by 25 (Europe PMC)

PMID12174922 (opens in a new tab)PepBankPUB-12174922
Publisher pageAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In the interim breast cancer analysis, recurrence-free survival did not differ between leuprorelin and CMF.

    In plain wordsIn the interim breast cancer analysis, recurrence-free survival did not differ between leuprorelin and CMF chemotherapy.

    Peptide
    Leuprolide
    Outcome
    No significant changeRecurrence-free survival
    Study

    n = 227

    Comparator
    CMF chemotherapy
    Analysis
    Primary
    Outcome group
    Tumor growth · Cancer
    Studied dose
    11.25 mg every three months · subcutaneous · Planned treatment: 2 yearsAs given in this study (human).

    Source sentences

    Summary
    So far, no difference between the groups has emerged with respect to recurrence-free or overall survivaL
    2 context sentences
    Summary · context
    The objective of this study was to evaluate the efficacy and tolerability of leuprorelin acetate in adjuvant treatment in comparison to standard chemotherapy with CMF in premenopausal, estrogen-receptor-positive or unknown, node-positive patients with early breast cancer.
    Summary · context
    The patients were randomly assigned to receive either 2 years of hormone ablation with leuprorelin acetate 11.25 mg as a subcutaneous injection every three months or six courses of CMF (cyclophosphamide 500 mg/m2, methotrexate 40 mg/m2, fluorouracil 600 mg/m2, days 1 and 8, q 4 weeks).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In the interim breast cancer analysis, overall survival did not differ between leuprorelin and CMF.

    In plain wordsIn the interim breast cancer analysis, overall survival did not differ between leuprorelin and CMF chemotherapy.

    Peptide
    Leuprolide
    Outcome
    No significant changeOverall survival
    Study

    n = 227

    Comparator
    CMF chemotherapy
    Analysis
    Secondary
    Outcome group
    Mortality · Cancer
    Studied dose
    11.25 mg every three months · subcutaneous · Planned treatment: 2 yearsAs given in this study (human).

    Source sentences

    Summary
    So far, no difference between the groups has emerged with respect to recurrence-free or overall survivaL
    2 context sentences
    Summary · context
    The objective of this study was to evaluate the efficacy and tolerability of leuprorelin acetate in adjuvant treatment in comparison to standard chemotherapy with CMF in premenopausal, estrogen-receptor-positive or unknown, node-positive patients with early breast cancer.
    Summary · context
    The patients were randomly assigned to receive either 2 years of hormone ablation with leuprorelin acetate 11.25 mg as a subcutaneous injection every three months or six courses of CMF (cyclophosphamide 500 mg/m2, methotrexate 40 mg/m2, fluorouracil 600 mg/m2, days 1 and 8, q 4 weeks).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In women with early breast cancer, leuprorelin suppressed serum estradiol more than CMF.

    In plain wordsIn women with early breast cancer, leuprorelin suppressed estradiol more than CMF chemotherapy.

    Peptide
    Leuprolide
    Outcome
    DecreaseSerum estradiol levels
    Study

    n = 227

    Comparator
    CMF chemotherapy
    Analysis
    Secondary
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    11.25 mg every three months · subcutaneous · Planned treatment: 2 yearsAs given in this study (human).

    Source sentences

    Summary
    Suppression of serum estradiol levels and menstruation was less marked in the CMF-group compared to the leuprorelin arm.
    2 context sentences
    Summary · context
    The objective of this study was to evaluate the efficacy and tolerability of leuprorelin acetate in adjuvant treatment in comparison to standard chemotherapy with CMF in premenopausal, estrogen-receptor-positive or unknown, node-positive patients with early breast cancer.
    Summary · context
    The patients were randomly assigned to receive either 2 years of hormone ablation with leuprorelin acetate 11.25 mg as a subcutaneous injection every three months or six courses of CMF (cyclophosphamide 500 mg/m2, methotrexate 40 mg/m2, fluorouracil 600 mg/m2, days 1 and 8, q 4 weeks).
  4. 04HumanRandomized controlled trialEfficacy outcome

    In women with early breast cancer, leuprorelin suppressed menstruation more than CMF.

    In plain wordsIn women with early breast cancer, leuprorelin suppressed menstruation more than CMF chemotherapy.

    Peptide
    Leuprolide
    Outcome
    DecreaseMenstruation
    Study

    n = 227

    Comparator
    CMF chemotherapy
    Analysis
    Secondary
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    11.25 mg every three months · subcutaneous · Planned treatment: 2 yearsAs given in this study (human).

    Source sentences

    Summary
    Suppression of serum estradiol levels and menstruation was less marked in the CMF-group compared to the leuprorelin arm.
    2 context sentences
    Summary · context
    The objective of this study was to evaluate the efficacy and tolerability of leuprorelin acetate in adjuvant treatment in comparison to standard chemotherapy with CMF in premenopausal, estrogen-receptor-positive or unknown, node-positive patients with early breast cancer.
    Summary · context
    The patients were randomly assigned to receive either 2 years of hormone ablation with leuprorelin acetate 11.25 mg as a subcutaneous injection every three months or six courses of CMF (cyclophosphamide 500 mg/m2, methotrexate 40 mg/m2, fluorouracil 600 mg/m2, days 1 and 8, q 4 weeks).
  5. 05HumanNon-randomized trialSafety outcome

    In women with early breast cancer, low-grade hot flushes were among the most common adverse events with leuprorelin.

    In plain wordsIn women with early breast cancer, low-grade hot flushes were among the most common adverse events with leuprorelin.

    Peptide
    Leuprolide
    Outcome
    Not applicableLow-grade hot flushes
    Study

    n = 110

    Analysis
    Secondary
    Outcome group
    Adverse events · Whole body
    Studied dose
    11.25 mg every three months · subcutaneous · Planned treatment: 2 yearsAs given in this study (human).

    Source sentences

    Summary
    The most common adverse events were low-grade hot flushes, weight gain and increased sweating in the leuprorelin-treated patients and alopecia, nausea and vomiting in the CMF-group.
    2 context sentences
    Summary · context
    The objective of this study was to evaluate the efficacy and tolerability of leuprorelin acetate in adjuvant treatment in comparison to standard chemotherapy with CMF in premenopausal, estrogen-receptor-positive or unknown, node-positive patients with early breast cancer.
    Summary · context
    The patients were randomly assigned to receive either 2 years of hormone ablation with leuprorelin acetate 11.25 mg as a subcutaneous injection every three months or six courses of CMF (cyclophosphamide 500 mg/m2, methotrexate 40 mg/m2, fluorouracil 600 mg/m2, days 1 and 8, q 4 weeks).
  6. 06HumanNon-randomized trialSafety outcome

    In women with early breast cancer, weight gain was among the most common adverse events with leuprorelin.

    In plain wordsIn women with early breast cancer, weight gain was among the most common adverse events with leuprorelin.

    Peptide
    Leuprolide
    Outcome
    IncreaseWeight gain
    Study

    n = 110

    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    11.25 mg every three months · subcutaneous · Planned treatment: 2 yearsAs given in this study (human).

    Source sentences

    Summary
    The most common adverse events were low-grade hot flushes, weight gain and increased sweating in the leuprorelin-treated patients and alopecia, nausea and vomiting in the CMF-group.
    2 context sentences
    Summary · context
    The objective of this study was to evaluate the efficacy and tolerability of leuprorelin acetate in adjuvant treatment in comparison to standard chemotherapy with CMF in premenopausal, estrogen-receptor-positive or unknown, node-positive patients with early breast cancer.
    Summary · context
    The patients were randomly assigned to receive either 2 years of hormone ablation with leuprorelin acetate 11.25 mg as a subcutaneous injection every three months or six courses of CMF (cyclophosphamide 500 mg/m2, methotrexate 40 mg/m2, fluorouracil 600 mg/m2, days 1 and 8, q 4 weeks).
  7. 07HumanNon-randomized trialSafety outcome

    In women with early breast cancer, increased sweating was among the most common adverse events with leuprorelin.

    In plain wordsIn women with early breast cancer, increased sweating was among the most common adverse events with leuprorelin.

    Peptide
    Leuprolide
    Outcome
    IncreaseIncreased sweating
    Study

    n = 110

    Analysis
    Secondary
    Outcome group
    Adverse events · Whole body
    Studied dose
    11.25 mg every three months · subcutaneous · Planned treatment: 2 yearsAs given in this study (human).

    Source sentences

    Summary
    The most common adverse events were low-grade hot flushes, weight gain and increased sweating in the leuprorelin-treated patients and alopecia, nausea and vomiting in the CMF-group.
    2 context sentences
    Summary · context
    The objective of this study was to evaluate the efficacy and tolerability of leuprorelin acetate in adjuvant treatment in comparison to standard chemotherapy with CMF in premenopausal, estrogen-receptor-positive or unknown, node-positive patients with early breast cancer.
    Summary · context
    The patients were randomly assigned to receive either 2 years of hormone ablation with leuprorelin acetate 11.25 mg as a subcutaneous injection every three months or six courses of CMF (cyclophosphamide 500 mg/m2, methotrexate 40 mg/m2, fluorouracil 600 mg/m2, days 1 and 8, q 4 weeks).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.